🚨 Missed it? Catch up on the Stroke Alert Podcast featuring @TotoMynell on the DO-IT Target Trial Analysis — key insights into thrombolysis in DOAC-treated stroke patients. Don’t miss this one! 🎧 Stroke Alert October 2025

ICYMI: CME available for #Stroke article "Intravenous Thrombolysis in Patients With Recent Intake of Direct Oral Anticoagulants: A Target Trial Analysis and Comparison With Reversal Agent Use" by @TotoMynell et al.

The ICH checklist is out, please use it! by Andrea Morotti @DavidSeiffge @PrCCordonnier @stephanamayer & the CODE-ICH team #stroke #intracerebralhemorrhage #timeisbrain https://t.co/0rr1pnUeT0

Enjoyed October #Strokealert podcast and conversation between @NAsdaghi and @TotoMynell on use of lysis with previous DOAC use. The DO-IT trial will be a potential game changer @StrokeAHA_ASA @ESOstroke

¿Y si pudieras aprender directamente de quienes están transformando el cuidado del ACV en el mundo? 🔍 Del 2 al 5 de diciembre, São Paulo será sede del Latin America Stroke Summer School, un evento único que reúne a especialistas de toda la región en una experiencia práctica,

In Get With The Guidelines-Stroke registry, patients with ICH & subtherapeutic warfarin anticoagulation (INR 1.5–1.9), reversal was not linked to better functional outcomes, but was associated with 25% lower in-hospital mortality and longer hospital stay. https://t.co/zYEweNvCdu

Patent Foramen Ovale and Stroke: A Review

📣 Calling all stroke specialists in Latin America! Join us in São Paulo, Dec 2–5 2025, for the first Latin America Stroke Summer School from University of Bern in partnership with Rede Brasil AVC and ESO, endorsed by WSO. 🎥 Check out Urs Fischer’s invitation and get ready for

In patients with chronic coronary syndrome taking oral anticoagulants, adding aspirin led to higher risks of cardiovascular events, major bleeding, and death from any cause than anticoagulation alone. DO NOT ADD ASS TO (D)OAC for chronic CAD https://t.co/gD41INxSv0

Cancer-related strokes are difficult to manage, synonym of bad prognosis and still poorly understood, which is why I did my clinical PhD on this exciting topic. It is now published online, check it out!😉: https://t.co/MXBX4F0WMR @StrokeBern @MedFacultyUniBE

🔊 Exciting DO-IT Trial Update! 🔊 🌍 📈 Just this week, we received final regulatory approval for additional sites in Germany, Spain, the Netherlands and Belgium through CTIS. Thus, a total of 52 sites have already been approved! 🇩🇪🇪🇸🇳🇱🇧🇪 💉🧑‍⚕️Small Steps. Big Impact. DO-IT!

🔊 Exciting DO-IT Trial Update!🔊 📈 🌍 The trial continues to expand, with 24 sites actively recruiting across Europe and 33 patients enrolled so far! - 27 in🇨🇭 - 3 in the 🇳🇱 - 2 in 🇧🇪 - 1 in 🇪🇸 👏 A big thank you to everyone contributing! 💉🧑‍⚕️Recruit. Care. Cure. DO-IT!

Impact of hypertension on cerebral small vessel disease: A post-mortem study of microvascular pathology from normal-appearing white matter into white matter hyperintensities🧠

An outstanding primeview on the ISPS25 stroke classification system @WorldStrokeOrg #WSC25 from @ShadiYaghi2

Excited to see our work "SWICH - a fully automated deep learning model for CT-based ICH segmentation" presented by @bmsiepen at the World Stroke Conference 2025 in Barcelona! 🎉 Open-access software available - contact our team to collaborate or try it out. #WSC2025

@DavidSeiffge on novel options for #afib patients with breakthrough #stroke. @ELAPSETrial testing #LAAO might be the breakthrough for breakthrough? #WSC2025 @StrokeBern @FishingNeurons @RaberLorenz

Delighted to be at WorldStrokeCongress2025! Management of cardioembolic stroke is rapidly changing ➡️➡️ 🟡Look for LAA shape @SposatoL 🟢consider LAAO option @DavidSeiffge 🔴think of optimal anticoagulation strategies #WSC2025 @worldstroke

The pleasure was all mine. Thanks so much for the interest and the fantastic Podcast with all the latest #stroke evidence!👍🙏🧠🫀 Let's @DOIT_trial ! @StrokeBern @DavidSeiffge @lucianacatanese

🚨Exciting DO-IT Trial Update!🚨 Co-funding has been granted from PHRC-N for France. A big thank you to Guillaume Turc and their teams for this great accomplishment.

Avoiding thrombolysis in #DOAC users is a legacy from concerns in VitK antagonist era. A pleasure interviewing ⁦@TotoMynell⁩ — a new dawn with the #DOIT trial ⁦@StrokeAHA_ASA⁩.